SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

14 Nov 2022 Evaluate
The sales for the September 2022 quarter moved down -59.13% to Rs. 487.40 millions as compared to Rs. 1192.60 millions during the year ago period.The Net Loss for the quarter ended September 2022 is Rs. -68.50 millions as compared to Net Loss of Rs. -223.70 millions of corresponding quarter ended September 2021 Operating profit Margin for the quarter ended September 2022 improved to 16.00% as compared to -139.80% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 487.40 1192.60 -59.13 1100.80 1555.20 -29.22 2355.00 3435.60 -31.45
Other Income 79.20 34.70 128.24 144.50 76.20 89.63 125.70 207.40 -39.39
PBIDT 16.00 -139.80 -111.44 -638.90 -292.40 118.50 -601.10 212.40 -383.00
Interest 22.10 19.10 15.71 46.80 36.90 26.83 70.40 75.20 -6.38
PBDT -6.10 -158.90 -96.16 -685.70 -329.30 108.23 -671.50 137.20 -589.43
Depreciation 62.40 64.80 -3.70 125.20 129.10 -3.02 264.30 265.70 -0.53
PBT -68.50 -223.70 -69.38 -810.90 -458.40 76.90 -935.80 -128.50 628.25
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.60 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.10 0.00
PAT -68.50 -223.70 -69.38 -810.90 -458.40 76.90 -935.80 -144.10 549.41
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 3.28 -11.72 -128.00 -58.04 -18.80 208.70 -25.52 6.18 -512.86

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×